ArticlePsychological trauma : theory, research, practice and policy2026
Evaluating cognitive effects of topiramate in trauma-focused treatment: Findings from a randomized double-blind clinical trial of veterans with PTSD and alcohol use disorder.
Article in Psychological trauma : theory, research, practice and policy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveVeterans with comorbid posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) often experience more severe symptoms, functional impairments, challenges in treatment engagement, and worse treatment outcomes than veterans with either disorder alone. Although topiramate is an effective pharmacotherapy for AUD and has shown promise in reducing PTSD symptoms, concerns about its potential cognitive side effects may deter prescribing providers and contribute to patient hesitancy. This study aimed to determine whether topiramate leads to adverse cognitive side effects that could impede its suitability to be used in tandem with prolonged exposure for PTSD and AUD.
methodData were analyzed from a double-blind, placebo-controlled trial in which 100 veterans with PTSD and AUD were randomized to receive prolonged exposure with either topiramate or placebo. Cognitive functioning was assessed at baseline and midtreatment, and PTSD symptoms were assessed at baseline and posttreatment.
resultsResults showed no statistically significant differences between treatment groups in verbal learning and memory or processing speed performance at either time point, and all scores were within normal clinical ranges.
conclusionsWhile minor declines in some cognitive domains were observed in both the topiramate and placebo groups, these changes were nonsignificant and not clinically meaningful (<1 standard deviation change). These findings suggest that topiramate does not produce clinically significant cognitive impairment when combined with prolonged exposure and may enhance treatment response. Future research should examine the long-term cognitive and therapeutic effects of topiramate to guide shared decision making and optimize integrated treatment for veterans with PTSD and AUD. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.